OmniComm Systems, Inc.
TrialMaster electronic data capture suite selected for Phase I and Phase IIa studies
Fort Lauderdale, FL, May 28, 2014 –- OmniCOmniComm Systems, Inc. (OTCQB: OMCM), a leading global provider of clinical data management solutions for clinical trials, today announced that one of the world’s largest contract research organizations (CRO) with annual revenues exceeding $2 billion, selected TrialMaster electronic data capture technology (EDC) to meet its current and future data management requirements for their expanding number of Phase I and Phase IIa clinical studies. These studies are the important first step in determining the safety and tolerability of new drugs. They test how drugs are absorbed into the body, and the amount of time a drug stays in the body. The drug’s safety and side effects are also evaluated at varying dose levels during these studies.
TrialMaster’s intuitive user interface made it the ideal choice for this CRO’s Phase I and Phase IIa studies. Additionally, TrialMaster’s single interface for data capture, data management and reporting was a significant factor in their selection of TrialMaster. TrialMaster’s web-based technology provides investigators and this CRO complete access to clinical data. TrialMaster’s ability to integrate with other clinical technologies such as safety systems is another significant feature that drove the selection. TrialMaster also includes embedded eLearning, allowing their researchers to easily learn the system and quickly and accurately initiate trials.
“This is another clear signal from the market that OmniComm is viewed as the EDC specialist company,” said Dr. Kuno van der Post, senior vice president of business development, OmniComm Systems. “It is not just performance, reliability and scalability that make TrialMaster EDC ideal for Phase I and II trials but also its feature rich functionality that enables rapid trial set up, ensures data accuracy, and improves clinical trial productivity."
About OmniComm Systems
OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world’s pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.OmniComm.com.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm and TrialMaster are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.